Recent Updates
Recently added Catalysts
ACB Positive Sentiment Score: 70/100

Aurora Cannabis Denies News of Acquisition of MedLeaf Therapeutics NASDAQ | TSX

Key Takeaway: Aurora Cannabis announced that it has not agreed to acquire MedLeaf Therapeutics, addressing misinformation circulating on news websites. The company emphasized that there have been no discussions regarding a business combination with MedLeaf. Additionally, it has released its financial statements for the fourth quarter and fiscal year ending March 31, 2025. The announcement reinforces Aurora's commitment to transparency and its ongoing operations in the cannabis sector.

Market Sentiment Analysis

POSITIVE FACTORS

  • Aurora Cannabis has clarified misinformation regarding an acquisition attempt, showing proactive communication.
  • The company remains focused on its medical and adult-use cannabis markets without distractions from false reports.

Full Press Release Details

Aurora Cannabis Denies News of Acquisition of
MedLeaf Therapeutics
EDMONTON, AB, June 18, 2025 /CNW/ - Aurora Cannabis
Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis
company, has become aware of misinformation posted on a news website, incorrectly stating that Aurora has agreed to acquire New Zealand
based MedLeaf Therapeutics. The Company has not entered into any such agreement, has had no discussions with MedLeaf Therapeutics with
respect to any business combination transaction, and has not made any statement or filed any information pertaining to any such transaction.
Earlier today before market open, Aurora filed the
Company's financial statements and management's discussion and analysis for the fourth quarter and fiscal year ending March 31, 2025.
All information pertaining to these disclosures is available on the Company's website at www.auroramj.com and on SEDAR+ and EDGAR.
About Aurora Cannabis
Aurora is opening the world to cannabis, serving both
the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer
in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael
'71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana
Co., as well as international brands, Pedanios, Bidiol, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd.,
North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality
cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets
Aurora's common shares trade on the NASDAQ and TSX
under the symbol "ACB".
Forward Looking Information
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable securities law ("forward-looking statements").
Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project",
"intend", "believe", "anticipate", "estimate", "may", "will", "potential",
"proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur.
These forward-looking statements are only predictions.
Forward looking information or statements contained in this news release have been developed based on assumptions management considers
to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly
available information from governmental sources as well as from market research and industry analysis and on assumptions based on data
and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks,
uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events,
results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking
statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods
imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure
to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and
retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand
in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the ability to expand and
maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis
growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules,
and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out
under the heading "Risk Factors" in the Company's annual information form dated June 17, 2025 (the "AIF") and
filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with
and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described
in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties
and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information.
The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
SOURCE Aurora Cannabis Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2025/18/c3927.html
For further information: For Media: Michelle Lefler, VP, Communications
& PR, media@auroramj.com; For Investors: ICR, Inc., Investor Relations, aurora@icrinc.com
CO: Aurora Cannabis Inc.
CNW 16:34e 18-JUN-25

Frequently Asked Questions

Did Aurora Cannabis acquire MedLeaf Therapeutics?

No, Aurora has not acquired MedLeaf Therapeutics and denies any such reports.

Has Aurora discussed a transaction with MedLeaf?

Aurora has not had any discussions regarding a business transaction with MedLeaf.

Where can I find Aurora's latest financial disclosures?

Aurora's financial statements are available on their website and on SEDAR+.

What brands does Aurora Cannabis offer?

Aurora's brands include MedReleaf, CanniMed, and several adult-use portfolios.

What stock exchanges does Aurora Cannabis trade on?

Aurora Cannabis shares are traded on NASDAQ and TSX under the symbol 'ACB'.

Last updated: Jun 18, 2025